These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35770735)

  • 1. Paradoxical reactions and biologic agents: a French cohort study of 9303 patients.
    Bataille P; Layese R; Claudepierre P; Paris N; Dubiel J; Amiot A; Sbidian E;
    Br J Dermatol; 2022 Nov; 187(5):676-683. PubMed ID: 35770735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
    Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
    Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study.
    Yagiz B; Lermi N; Coskun BN; Dalkilic E; Kiraz S; Erden A; Ertenli I; Duran E; Bilgin E; Yılmaz R; Ateş A; Tufan A; Küçük H; Mercan R; Cinaklı H; Akar S; Yaşar Bilge NŞ; Kaşifoglu T; Türk SM; Gonullu EO; Bes C; Alpay Kanitez N; Emmungil H; Kalyoncu U; Pehlivan Y
    Rheumatology (Oxford); 2023 Dec; 62(12):3962-3967. PubMed ID: 37354493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
    Peer FC; Miller A; Pavli P; Subramaniam K
    Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
    Ward D; Nyboe Andersen N; Gørtz S; Thorn Iversen A; Højgaard Allin K; Beaugerie L; Kirchgesner J; Jess T
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):135-143.e8. PubMed ID: 37442315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
    Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
    Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
    [No Abstract]   [Full Text] [Related]  

  • 12. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
    Chiu YM; Chen DY
    Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis.
    Yang M; Liu W; Deng Q; Liang Z; Wang Q
    Medicine (Baltimore); 2021 Oct; 100(42):e27510. PubMed ID: 34678884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
    Borren NZ; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Esse S; Mason KJ; Green AC; Warren RB
    JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
    Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
    J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
    Townsend CM; Lovegrove F; Khanna R; Wilson AS
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1379-1388. PubMed ID: 35312094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
    Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
    Puig L
    Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.